Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
Real-World Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy BLOOD 2021
First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib BLOOD 2021
Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial BLOOD 2021
Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A ``Campus CML{''} Study BLOOD 2021
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia BLOOD 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia EXPERT OPINION ON INVESTIGATIONAL DRUGS 2021
Measuring prognosis in chronic myeloid leukemia: what's new? EXPERT REVIEW OF HEMATOLOGY 2021
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice? CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib ANNALS OF HEMATOLOGY 2021
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis BLOOD CANCER JOURNAL 2021
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA) ANNALS OF HEMATOLOGY 2021
Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge JOURNAL OF CLINICAL MEDICINE 2021
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors EXPERT REVIEW OF HEMATOLOGY 2021
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients ANNALS OF HEMATOLOGY 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients HEMATOLOGICAL ONCOLOGY 2021
Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia FRONTIERS IN ONCOLOGY 2021
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged > 65 years resistant/intolerant to previous tyrosine-kinase inhibitors HEMATOLOGICAL ONCOLOGY 2021
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase FRONTIERS IN ONCOLOGY 2021
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome CANCER 2021
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2021

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma